Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2020

01-12-2020 | Breast Cancer | Correction

Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study

Authors: Danielle H. Bodicoat, Minouk J. Schoemaker, Michael E. Jones, Emily McFadden, James Griffin, Alan Ashworth, Anthony J. Swerdlow

Published in: Breast Cancer Research | Issue 1/2020

Login to get access

Excerpt

Correction to: Breast Cancer Res …
Literature
1.
Metadata
Title
Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study
Authors
Danielle H. Bodicoat
Minouk J. Schoemaker
Michael E. Jones
Emily McFadden
James Griffin
Alan Ashworth
Anthony J. Swerdlow
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2020
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-020-1257-2

Other articles of this Issue 1/2020

Breast Cancer Research 1/2020 Go to the issue

Research article

CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress

Research article

MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth

Research article

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer

Research article

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

Research article

Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells

Research article

Perinatal and postnatal exposures and risk of young-onset breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits